Salbutamol
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Salbutamol: Papillary conjunctivitis
One-Sentence Summary
Salbutamol is a short-acting beta-2 adrenergic agonist that is marketed in Canada in several inhaled and injectable products. The TxGNN model predicts it may be effective for papillary conjunctivitis, with a score of 0.9999. However, no clinical trials and no publications were found for this disease, so the prediction currently rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Papillary conjunctivitis |
| TxGNN Prediction Score | 1.0000 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 15 of 15) |
| Number of DINs | 15 (marketed: 15) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for this drug. Based on general pharmacology, salbutamol activates beta-2 adrenergic receptors. Preclinical work on beta-2 agonists has suggested anti-inflammatory and mast-cell-stabilizing effects in conjunctival tissue, which could in theory be relevant to an allergic eye condition such as papillary conjunctivitis.
This link is speculative. No clinical trial or publication retrieved for this report studies salbutamol in papillary conjunctivitis, so the prediction cannot be considered supported beyond the model score. Because there is no direct study of this disease, the evidence level is L5.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02208229 | PMS-SALBUTAMOL | Not listed | Not listed |
| 02326450 | TEVA-SALBUTAMOL HFA | Not listed | Not listed |
| 02243115 | VENTOLIN DISKUS | Not listed | Not listed |
| 02241497 | VENTOLIN HFA | Not listed | Not listed |
| 02213486 | VENTOLIN RESPIRATOR SOLUTION | Not listed | Not listed |
All 15 licences in the local records are currently valid; the five above are shown as examples.
Safety Considerations
- Drug Interactions: 100 interactions were found in the interaction databases. Examples at moderate level include acarbose, epinephrine, famotidine, clarithromycin, cisapride, and several antidiabetic drugs (e.g., alogliptin, canagliflozin, dapagliflozin, chlorpropamide). Corticosteroids such as hydrocortisone, budesonide, and dexamethasone are listed at minor level.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is very high, but there are no clinical trials or publications on salbutamol in papillary conjunctivitis. The only supporting idea is a general, preclinical anti-inflammatory effect of beta-2 agonists in the conjunctiva, which is not enough to justify moving forward.
To proceed, the following is needed:
- Preclinical or early clinical data directly studying salbutamol, or a topical ocular formulation, in papillary conjunctivitis
- Mechanism of action data
- Assessment of whether an ocular route of administration is feasible, since the current Canadian products are inhaled or injectable
- Review of package insert warnings and contraindications, including cardiovascular and metabolic cautions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.